Qiagen, Bayer Partner on Cancer Companion Dx | GenomeWeb

NEW YORK (GenomeWeb News) – Qiagen today said that it will collaborate with Bayer HealthCare on developing companion diagnostics for Bayer drugs with an initial focus on those that target solid tumors.

The companion diagnostic tests will run on Qiagen's QIA symphony automated instruments. In addition, the partners said that they will collaborate on developing technologies for patient profiling, which may result on research-use-only products for exploratory and translational medicine, said Qiagen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.